Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
Oral GLP-1 Candidate Improves Blood Sugar and Weight in Phase 2b Trial
The SOLSTICE trial found that elecoglipron, an oral small-molecule GLP-1 receptor agonist, lowered glucose and weight in adults with type 2 diabetes, with results presented at ADA and published in The Lancet.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
Mass General Brigham reported results from SOLSTICE, a phase 2b randomized, placebo-controlled trial of elecoglipron, an oral small-molecule GLP-1 receptor agonist for adults with type 2 diabetes.
The trial enrolled 406 adults across nine countries and tested different starting doses, dose-escalation approaches and maintenance doses. Results were presented at the American Diabetes Association Scientific Sessions and published simultaneously in The Lancet.
After 26 weeks, elecoglipron lowered glucose more than placebo across tested doses. Up to 89.6% of participants receiving the drug reached an HbA1c level of 7%, compared with 24.9% in the placebo group.
The study also reported weight effects: up to 72.3% of people taking elecoglipron achieved at least 5% body-weight reduction, compared with 20.2% on placebo. Researchers said the safety and tolerability profile was broadly consistent with other GLP-1 therapies at this stage.
Sourcing note: Trial size, endpoints and results are from Mass General Brigham via ScienceDaily and the Lancet citation. The trial was funded by AstraZeneca, and author disclosures are part of the source record.
Why It Matters
Injectable GLP-1 drugs have reshaped diabetes and obesity care, but route, dosing and access remain practical barriers. A small-molecule oral GLP-1 with strong phase 2b data could broaden the field if later trials confirm efficacy, safety, adherence advantages and manufacturing scale.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
GLP-1Type 2 DiabetesElecoglipronThe LancetMass General Brigham